This website is intended for UK Healthcare Professionals only. Not a UK Healthcare Professional? Click here

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events reporting information can be found at the bottom of this page.

INTRODUCING NEXPOVIO®

NEXPOVIO® (selinexor) is indicated for the treatment of adult patients with multiple myeloma:

in combination with bortezomib and dexamethasone for those who have received at least one prior myeloma treatment1

in combination with just dexamethasone for those who have received at least four previous types of myeloma treatment1

NEXPOVIO® Mechanism of Action

NEXPOVIO® is a first-in-class oral inhibitor of XPO1, offering a unique MoA for the treatment of RRMM1–4

NICE RECOMMENDATION

NEXPOVIO® is now recommended by NICE and is available for use on the NHS for patients with RRMM5,6

EXPLORE KEY data AND BEST PRACTICE USE OF NEXPOVIO®

Dr Karthik Ramasamy
Key NEXPOVIO® clinical trial data

Dr Neil Rabin
How to prescribe NEXPOVIO® and manage adverse reactions

Prof Evangelos Terpos
Clinical experience of using NEXPOVIO® in Greece

If you’d like to find out more about NEXPOVIO®, contact your local representative today.